MetLife Investment Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.28M | Sell |
34,279
-876
| -2% | -$161K | 0.03% | 525 |
|
|
2025
Q4 | $6.19M | Sell |
35,155
-1,210
| -3% | -$198K | 0.03% | 532 |
|
|
2025
Q3 | $5.09M | Sell |
36,365
-960
| -3% | -$130K | 0.02% | 630 |
|
|
2025
Q2 | $4.69M | Sell |
37,325
-677
| -2% | -$84.4K | 0.03% | 606 |
|
|
2025
Q1 | $5.2M | Sell |
38,002
-562
| -1% | -$80.3K | 0.03% | 593 |
|
|
2024
Q4 | $5.9M | Buy |
38,564
+690
| +2% | +$116K | 0.03% | 468 |
|
|
2024
Q3 | $7.34M | Sell |
37,874
-962
| -2% | -$201K | 0.04% | 354 |
|
|
2024
Q2 | $9M | Buy |
38,836
+4,926
| +15% | +$1.07M | 0.05% | 266 |
|
|
2024
Q1 | $7.31M | Sell |
33,910
-1,248
| -4% | -$292K | 0.05% | 322 |
|
|
2023
Q4 | $9.1M | Sell |
35,158
-648
| -2% | -$159K | 0.07% | 237 |
|
|
2023
Q3 | $9.2M | Sell |
35,806
-919
| -3% | -$246K | 0.07% | 220 |
|
|
2023
Q2 | $10.5M | Sell |
36,725
-423
| -1% | -$126K | 0.08% | 203 |
|
|
2023
Q1 | $10.3M | Sell |
37,148
-446
| -1% | -$123K | 0.07% | 201 |
|
|
2022
Q4 | $10.4M | Sell |
37,594
-937
| -2% | -$265K | 0.08% | 203 |
|
|
2022
Q3 | $10.3M | Sell |
38,531
-907
| -2% | -$193K | 0.09% | 187 |
|
|
2022
Q2 | $8.04M | Sell |
39,438
-518
| -1% | -$106K | 0.06% | 248 |
|
|
2022
Q1 | $8.41M | Buy |
39,956
+7,501
| +23% | +$1.63M | 0.05% | 294 |
|
|
2021
Q4 | $7.79M | Sell |
32,455
-1,206
| -4% | -$310K | 0.06% | 249 |
|
|
2021
Q3 | $9.53M | Sell |
33,661
-1,245
| -4% | -$408K | 0.09% | 189 |
|
|
2021
Q2 | $12.1M | Sell |
34,906
-1,396
| -4% | -$423K | 0.11% | 158 |
|
|
2021
Q1 | $10.2M | Sell |
36,302
-1,069
| -3% | -$288K | 0.09% | 171 |
|
|
2020
Q4 | $9.15M | Sell |
37,371
-2,769
| -7% | -$714K | 0.09% | 186 |
|
|
2020
Q3 | $11.4M | Sell |
40,140
-2,539
| -6% | -$708K | 0.12% | 147 |
|
|
2020
Q2 | $11.4M | Sell |
42,679
-3,833
| -8% | -$1.15M | 0.13% | 149 |
|
|
2020
Q1 | $14.7M | Sell |
46,512
-1,423
| -3% | -$432K | 0.2% | 99 |
|
|
2019
Q4 | $14.2M | Sell |
47,935
-2,260
| -5% | -$627K | 0.15% | 129 |
|
|
2019
Q3 | $11.7M | Sell |
50,195
-3,250
| -6% | -$757K | 0.13% | 153 |
|
|
2019
Q2 | $12.5M | Sell |
53,445
-2,472
| -4% | -$571K | 0.13% | 140 |
|
|
2019
Q1 | $13.2M | Sell |
55,917
-1,704
| -3% | -$537K | 0.14% | 128 |
|
|
2018
Q4 | $17.3M | Sell |
57,621
-980
| -2% | -$313K | 0.21% | 89 |
|
|
2018
Q3 | $20.7M | Sell |
58,601
-3,515
| -6% | -$1.21M | 0.21% | 84 |
|
|
2018
Q2 | $18M | Sell |
62,116
-1,552
| -2% | -$436K | 0.21% | 79 |
|
|
2018
Q1 | $17.4M | Sell |
63,668
-1,751
| -3% | -$544K | 0.21% | 92 |
|
|
2017
Q4 | $20.8M | Buy |
+65,419
| New | +$21M | 0.24% | 77 |
|
Other funds holding BIIB
VCM
VPM
MetLife Investment Management's BIIB Position: Q1 2026 in Review
MetLife Investment Management reduced its Biogen (BIIB) stake by 2.5% in Q1 2026, selling an estimated $161K and leaving 34,279 shares worth $6.28M. The position accounts for 0.03% of the portfolio, ranked #525.
MetLife Investment Management first reported a position in BIIB in Q4 2017 and has held it in 34 quarters since. The position peaked at $20.8M in Q4 2017. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- MetLife Investment Management held 34,279 shares of Biogen worth $6.28M as of Q1 2026.
- MetLife Investment Management sold 876 Biogen shares in Q1 2026, an estimated $161K.
- Biogen made up 0.03% of MetLife Investment Management's portfolio in Q1 2026, its #525 holding.
- MetLife Investment Management first reported a position in Biogen in Q4 2017 and has held it in 34 quarters since.
- MetLife Investment Management's Biogen position peaked at $20.8M in Q4 2017.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.